[PDF][PDF] American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003
DG Pfister, DH Johnson, CG Azzoli… - Journal of Clinical …, 2004 - scholar.archive.org
The American Society of Clinical Oncology (ASCO) previously published evidencebased
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …
guidelines for the treatment of unresectable non–small-cell lung cancer (NSCLC)[1]. ASCO …
Prophylactic cranial irradiation for patients with lung cancer
C Le Péchoux, A Sun, BJ Slotman… - The Lancet …, 2016 - thelancet.com
The incidence of brain metastases in patients with lung cancer has increased as a result of
improved local and systemic control and better diagnosis from advances in brain imaging …
improved local and systemic control and better diagnosis from advances in brain imaging …
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase …
CA Meyers, JA Smith, A Bezjak, MP Mehta… - Journal of clinical …, 2004 - ascopubs.org
Purpose To report the neurocognitive findings in a phase III randomized trial evaluating
survival and neurologic and neurocognitive function in patients with brain metastases from …
survival and neurologic and neurocognitive function in patients with brain metastases from …
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non–small-cell lung cancer: neurocognitive and quality-of …
A Sun, K Bae, EM Gore, B Movsas, SJ Wong… - Journal of clinical …, 2011 - ascopubs.org
Purpose There are scant data regarding the effects of prophylactic cranial irradiation (PCI)
on neurocognitive function (NCF) and quality of life (QOL). Radiation Therapy Oncology …
on neurocognitive function (NCF) and quality of life (QOL). Radiation Therapy Oncology …
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
MP Mehta, P Rodrigus, CHJ Terhaard… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: This phase III randomized trial evaluated survival as well as neurologic and
neurocognitive function in patients with brain metastases from solid tumors receiving whole …
neurocognitive function in patients with brain metastases from solid tumors receiving whole …
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non–small-cell lung cancer: primary analysis of radiation …
EM Gore, K Bae, SJ Wong, A Sun, JA Bonner… - Journal of Clinical …, 2011 - ascopubs.org
Purpose This study was conducted to determine if prophylactic cranial irradiation (PCI)
improves survival in locally advanced non–small-cell lung cancer (LA-NSCLC). Patients and …
improves survival in locally advanced non–small-cell lung cancer (LA-NSCLC). Patients and …
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or …
S Heon, BY Yeap, GJ Britt, DB Costa, MS Rabin… - Clinical cancer …, 2010 - AACR
Purpose: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
elicit responses in patients with brain metastases (BM) from non–small cell lung cancer …
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
AMP Omuro, MG Kris, VA Miller… - … Journal of the …, 2005 - Wiley Online Library
BACKGROUND Gefitinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
induces an early and dramatic response in 10% of patients with advanced nonsmall cell …
induces an early and dramatic response in 10% of patients with advanced nonsmall cell …
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
DC Betticher, SF Hsu Schmitz, M Tötsch… - British journal of …, 2006 - nature.com
The aim was to investigate the efficacy of neoadjuvant docetaxel–cisplatin and identify
prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non …
prognostic factors for outcome in locally advanced stage IIIA (pN2 by mediastinoscopy) non …
Time from treatment to subsequent diagnosis of brain metastases in stage III non–small-cell lung cancer: a retrospective review by the Southwest Oncology Group
LE Gaspar, K Chansky, KS Albain… - Journal of Clinical …, 2005 - ascopubs.org
Purpose A retrospective review of the Southwest Oncology Group (SWOG) database was
undertaken to review the incidence and timing of diagnosis of brain metastases in patients …
undertaken to review the incidence and timing of diagnosis of brain metastases in patients …